Open Fri 8:30am : 01582 842096
VioVet Insurance
FREE DELIVERY on most orders over £29
  • 5mg Tablets » Priced per Tablet £0.61
  • 20mg Tablets » Priced per Tablet £1.14
  • 80mg Tablets » Priced per Tablet £3.47
  • Injection 2% » 100ml Bottle £46.39
  • Injection 10% » 50ml Bottle £59.72
  • Injection 10% » 100ml Bottle £119.42

Selection of 6 products from

£0.61 to £119.42

Description

Marbocyl P is relatively recently developed antibiotic available in doses for use on dogs, cats, pigs and cattle. It has a broad spectrum of activity and can be used in infections affecting the skin, respiratory system, urinary systems and other soft tissues. Appropriate culture and sensitivity testing of the infectious agent is advised where possible. For mild and localised infections a course lasting a few days is all that is needed, but some infections, such as those involving the deeper layers of the skin, will require a course lasting several weeks. Marbocyl tablets should be given once daily

Marbocyl™ 10% Solution for Injection

Presentation

Solution for Injection. Each 100ml contains marbofloxacin 10g, monothioglycerol 0.1g, metacresol 0.2g and disodium edetate 0.01g

Uses

In cattle: Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E.coli mastitis.

In pigs: Indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by susceptible strains of organisms.

Dosage and administration

The recommended dose rate is 2mg/kg/day (1ml/50kg) in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs.

Treatment durations are 3 days in pigs and 3 to 5 days in cattle.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

Contra-indications, warnings, etc

Withdrawal periods

Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 36 hours from the last treatment.

Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 6 days from the last treatment. Pigs may be slaughtered for human consumption only after 4 days from the last treatment.

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

General precautions: No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively. In particular, no lesions of the articular joints are encountered.

Intramuscular or subcutaneous injections are well tolerated although transitory inflammatory lesions without clinical impact can occur at the injection site.

May be used in pregnant and lactating cows and sows.

Special precautions for use in animals

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevelance of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

Operator warnings

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Pharmaceutical precautions

Do not store above 25°C and protect from light.

Following withdrawal of the first dose, use the product within 28 days. Any unused material should be discarded.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.

Legal category

POM-V

Packaging Quantities

Amber type II glass vials of 20, 50, 100 and 250ml. The vials are closed with a chlorobutyl rubber stopper oversealed within aluminium caps. Each vial is packaged in a cardboard box. Not all pack sizes may be marketed.

Further information

ATC Vet code: QJ01MA93

Pharmacodynamic properties:

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp) as well as Mycoplasma spp.

Pharmacokinetic properties:

After subcutaneous or intramuscular administration in cattle and intramuscular administration in pigs at the recommended dose of 2mg/kg, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5microgram/ml within less than 1 hour. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (less than 10% in pigs and 30% in cattle), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract) it achieves a higher concentration than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9h) but faster in ruminant cattle (t1/2β = 4-7h) predominantly in the active form in urine (¾ in pre-ruminating calves, ½ in ruminants) and faeces (¼ in pre-ruminating calves, ½ in ruminants).

In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10h) predominantly in the active form in urine (2/3) and faeces (1/3).

Marketing Authorisation Holder (if different from distributor)

Vetoquinol SA

Magny-Vernois

BP 189

70204 Lure

Cedex

France

Marketing authorisation number

Vm 06462/4003.

GTIN (Global Trade Item No)

Marbocyl 10% 50ml

03605870006359

Marbocyl 10% 100ml

03605870006366

Marbocyl™ 2% Solution for Injection

Presentation

Marbocyl 2% is presented as a sterile solution for injection.

Marbofloxacin 2.0% w/v

Disodium edetate 0.01% w/v

Thioglycerol 0.05% w/v

Metacresol 0.2% w/v

Uses

In pre-ruminant cattle up to 100kg bodyweight and pigs, Marbofloxacin 2 % is indicated in the treatment of respiratory infections caused by susceptible strains of organisms.

Dosage and administration

The recommended dosage is 2 mg/kg/day (1 ml/10 kg) in a single daily injection by subcutaneous or intravenous routes in cattle and by the intramuscular route in pigs.

Treatment duration is 3 - 5 days by the intravenous route in cattle, 3 days by the subcutaneous route in cattle, and 3 - 5 days by the intramuscular route in pigs.

The volume of injection should be limited to 10ml at each site of injection for pigs.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

Contra-indications, warnings, etc

Special Precautions for use in Animals

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Wherever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

No severe side-effects are to be expected at doses up to 5 times the recommended dose in cattle and pigs. In particular no lesions of the articular joints are encountered.

Subcutaneous injection is well tolerated. Transitory inflammatory reactions are sometimes observed at the injection site, but without clinical impact.

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

Operator Warning

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Withdrawal periods

Preruminating calves (up to 100kg bodyweight): 6 days

Pigs: 4 days

Pharmaceutical precautions

Following withdrawal of the first dose, use the product within 28 days. Discard unused material.

Do not store above 25°C. Protect from light.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.

Legal category

POM-V

Packaging Quantities

Packaged in amber type II glass vials of 10, 20, 50ml, 100 ml and 250ml.

The vials are closed with a chlorobutyl rubber stopper oversealed with aluminium caps.

Each vial is packaged in a cardboard box.

Not all pack sizes may be marketed.

Further information

ATC Vet Code: QJ01MA93

Pharmacodynamic properties

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Campylobacter jejunii, Citrobacter, Enterobacter, Proteus spp, Klebsiella spp Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella haemolytica, Pasteurella multocida, Haemophilus spp, Moraxella spp, Pseudononas aeruginosa) as well as Mycoplasma (Mycoplasma bovis, Mycoplasma dispar, Mycoplasma hyopneumoniae).

Resistance to Streptococcus may occur.

Pharmacokinetic properties

After subcutaneous administration in cattle and pigs at the recommended dose of 2 mg/kg, marbofloxacin is readily absorbed and its bioavailability is close to 100 %. It is weakly bound to plasma proteins (less than 10 % in pigs and 30 % in cattle), extensively distributed and, in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract), it achieves higher concentrations than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9 h) predominantly in the active form in urine (3/4) and faeces (1/4).

In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10 h) predominantly in the active form in urine (2/3) and faeces (1/3).

Marketing Authorisation Holder (if different from distributor)

Vetoquinol SA

Magny-Vernois

BP 189

70204 Lure

Cedex

France

Marketing authorisation number

Vm 06462/4005.

GTIN (Global Trade Item No)

Marbocyl 2%

03605870007387

Marbocyl P 5mg, 20mg and 80mg Tablets

Presentation

Beige brown spotted round tablets

Three strengths are available.

Marbocyl P 5 mg containing 5 mg marbofloxacin. For use in dogs and cats.

Marbocyl P 20 mg containing 20 mg marbofloxacin.For use in dogs.

Marbocyl P 80 mg containing 80 mg marbofloxacin. For use in dogs.

Uses

In Dogs

Marbocyl is indicated in the treatment of skin and soft tissue infections (skin fold pyoderma, impetigo, folliculitis, furunculosis, cellulitis), for the treatment of urinary tract infections associated or not with prostatitis and respiratory tract infections, caused by susceptible strains of organisms.

In Cats (Marbocyl P 5mg Tablet only)

Marbocyl is indicated for the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by susceptible strains of organisms.

Dosage and administration

For oral administration. The recommended dose rate is 2 mg/kg per day in a single daily administration. To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

In dogs for the treatment of skin and soft tissue infections, treatment duration is at least five days. Depending on the course of the disease it may be extended up to 40 days. In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease it may be extended up to 28 days. In respiratory infections, treatment duration is at least 7 days and, depending on the course of the disease, may be extended up to 21 days.

In cats for the treatment of skin and soft tissue infections, treatment duration is 3–5 days. For upper respiratory infections, treatment duration is 5 days.

Contra-indications, warnings, etc

Marbofloxacin should not be used in dogs aged less than 12 months or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs with a longer growth period. Not recommended for use in cats aged less than 16 weeks.

Not suitable for infections resulting from strict anaerobes, yeast or fungi.

Do not use Marbocyl P 20mg or Marbocyl P 80mg tablets in cats. For the treatment of this species the Marbocyl P 5mg tablet is available.

Special precautions for use in animals

The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately, especially in young animals.

The fluoroquinolones are known for their potential neurological side effects; cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy.

A low urinary pH could have an inhibitory effect on the activity of marbofloxacin.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly to other classes of antimicrobials. Whenever possible, use of fluoroquinolones should be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease effectiveness of treatment with other quinolones due to the potential for cross resistance.

Adverse reactions (frequency and seriousness)

At the therapeutic recommended dosage no severe side effects are to be expected in cats and dogs. In particular no lesions of the articular joints were encountered in clinical studies at the recommended dose rate.

Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of the treatment.

Use during pregnancy and lactation

Studies in pregnant rats and rabbits showed no side effects on pregnancy. However, no specific studies have been carried out in pregnant cats and dogs.

Interaction with other medicinal products and other forms of interaction

Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron.) In such cases, the bioavailability may be reduced.

Overdose (symptoms, emergency procedures, antidotes), if necessary

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

Withdrawal period(s)

Not applicable

Operator warning

People with known hypersensitivity to fluoroquinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wear gloves when handling or dividing tablets. Wash hands after use.

Pharmaceutical precautions

No special precautions for storage.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

POM-V

Packaging Quantities

Marbocyl P tablets are packaged in aluminium/aluminium blister packs.

Marbocyl P 5mg 10 blisters of 10 tablets

Marbocyl P 20mg 10 blisters of 10 tablets

Marbocyl P 80mg 12 blisters of 6 tablets

Further information

Pharmacodynamic properties

Marbofloxacin is a synthetic bactericidal antimicrobial belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci, Streptococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp, Brucella canis) as well as Mycoplasma spp.

Marbofloxacin is not effective against anaerobes, yeasts or fungi.

Resistance to fluoroquinolones occurs by chromosomal mutation with three mechanisms: decrease of the bacterial wall permeability, expression of the efflux pump or mutation of the enzymes responsible for molecule binding. No significant evolution of resistance to marbofloxacin has been observed in the target pathogenic strains isolated from companion animals since the launch of the molecule on the veterinary market. The occurrence and rate of transfer of a genetic resistance is therefore considered to be very low.

Cross-resistance with ß-lactam antibiotics, aminoglycosides, tetracyclines, macrolide and polypeptide antibiotics, sulfonamides, diaminopyrimidines, and nitrofurans does not generally occur. However, certain mutations conferring resistance to fluoroquinolones can also confer resistance to cephalosporins, tetracyclines, macrolides and chloramphenicol.

Pharmacokinetic properties

After oral administration in dogs and cats at the recommended dose of 2 mg/kg, Marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5 µg/ml within 2 hours. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (<10%), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma. Marbofloxacin is eliminated slowly (t1/2β= 14h in dogs and 10h in cats) predominately in the active form, in urine (2/3) and faeces (1/3).

Marketing authorisation number

Marbocyl P 5 mg Vm08007/4109.

Marbocyl P 20 mg Vm08007/4110.

Marbocyl P 80 mg Vm08007/4111.

GTIN (Global Trade Item No)

Marbocyl P 5mg

03605877310220

Marbocyl P 20mg

03605877310312

Marbocyl P 80mg

03605877310497

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Questions & Answers for Marbocyl

Below are some recent questions we've received regarding Marbocyl, including answers from our team.

Ask Your Own Question

Administration.

7th Sep 2014
HMR

Is Marbocyl available in a liquid oral form for reptiles. Would there be an adverse reaction giving the injectable for orally to a reptile?

John Cousins
  • Veterinary Surgeon

Strictly speaking this is something only your vet can advise you on, because he/she knows the full details of the case. I can say however that the injectable solution has been used in reptiles, either for injection or given orally, and it is regarded as generally safe and effective. The "recommended" dose is 10mg/kg every 2 days, but this is an unlicensed use and only your vet can advise on the specific risk/benefit analysis.